Aagami has received a new assignment as a result of one of the recently concluded BIO 2024 partnering event. The assignment has come from a past ...
Published : 23 Jun 2024
Read MoreAagami successfully completed BIO International Convention 2024 (June 3-6) in San Diego with 40+ one-on-one meetings with decision makers in Biotech, ...
Published : 10 Jun 2024
Read MoreNanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, has engaged Aag...
Published : 21 May 2024
Read MoreAagami, Inc. are pleased to announce that another US client has awarded a contract extension to support them in JV/Acquisition initiatives. We thank t...
Published : 15 May 2024
Read MoreAagami has won a New Client from Alabama, USA. The client is a clinical-stage biopharmaceutical company advancing the next generation of new anti-infl...
Published : 12 Mar 2024
Read MoreWe are pleased to announce that Aagami has received Contract Extension and Expansion of scope from its US based client. The client is an Awa...
Published : 20 Feb 2024
Read MoreWe are pleased to announce that Aagami CEO Dinesh Jain will be attending DCAT Week 2023 in person from MARCH 18 to 21 in New York City. If you or your...
Published : 09 Feb 2024
Read MoreSeveral months back, a Biosimilar focused subsidiary of a Global Pharma had appointed Aagami to help out-license their Market ready Denosumab Biosimil...
Published : 19 Jan 2024
Read MoreWe are pleased to announce that Aagami has received contract extension from its Japan and US based client. Client is a nose to brain [NtoB]...
Published : 10 Jan 2024
Read MoreHappy with the delivery of the first Assignment, our US based client has now appointed Aagami for Acquisition/Partnering for their Patented s...
Published : 12 Dec 2023
Read More